From: Clinical management of gastric cancer: results of a multicentre survey
Advanced practice | Recommendation of the Guidelines | Oncological surgeons | Medical oncologists | Radiation oncologists | p | |||
---|---|---|---|---|---|---|---|---|
 |  | N | % | N | % | N | % |  |
adenocarcinoma with solitary liver metastases | Systemic chemotherpy | Â | Â | Â | Â | Â | Â | 0.443 |
Systemic chemotherpy | Â | 4 | 3.96 | 7 | 4.35 | 5 | 5.21 | Â |
Liver lesion resection | Â | 8 | 7.92 | 16 | 9.94 | 5 | 5.21 | Â |
TACE | Â | 10 | 9.90 | 21 | 13.04 | 15 | 15.63 | Â |
Liver lesion resection + systemic chemotherpy | Â | 79 | 78.22 | 117 | 72.67 | 68 | 70.83 | Â |
Other | Â | 0 | 0 | 0 | 0 | 3 | 3.13 | Â |
adenocarcinoma with large quantity of ascites | Systemic chemotherpy | Â | Â | Â | Â | Â | Â | 0.210 |
Systemic chemotherapy | Â | 3 | 2.97 | 2 | 1.24 | 2 | 2.08 | Â |
intraperitoneal chemotherapy(IP) | Â | 4 | 3.96 | 6 | 3.73 | 5 | 5.21 | Â |
Systemic chemotherapy+IP | Â | 94 | 93.07 | 153 | 95.03 | 89 | 92.71 | 0.254 |
Other | Â | 0 | 0 | 0 | 0 | 0 | 0 | Â |
lungs metastases | Paclitaxel or docetaxel based regime or ECF(EPI+DDP+5FU) | Â | Â | Â | Â | Â | Â | 0.070 |
CF(DDP+5FU) | Â | 2 | 1.98 | 3 | 1.86 | 1 | 1.04 | Â |
ECF(EPI+DDP+5FU) | Â | 17 | 16.83 | 23 | 14.29 | 9 | 9.38 | Â |
Fluoropyrimidine(5Fu or Capecitabine) | Â | 13 | 12.87 | 12 | 7.45 | 14 | 14.58 | Â |
Oxaliplatin based regimen | Â | 33 | 32.67 | 51 | 31.68 | 25 | 26.04 | Â |
Irinotecan based regimen | Â | 9 | 8.91 | 22 | 13.66 | 15 | 15.63 | Â |
Paclitaxel or docetaxel based regime | Â | 25 | 24.75 | 46 | 28.57 | 29 | 30.21 | Â |
Combination of above or other | Â | 2 | 1.98 | 4 | 2.48 | 3 | 3.13 | Â |
lungs metastases, failure after ECF(EPI+DDP+5FU) | Change regimen and continue chemotherapy | Â | Â | Â | Â | Â | Â | Â |
Change regimen and continue chemotherapy | Â | 101 | 100 | 156 | 96.89 | 83 | 86.46 | 0.137 |
Best supportive care | Â | 0 | 0 | 2 | 1.24 | 9 | 9.38 | Â |
Other | Â | 0 | 0 | 3 | 1.86 | 4 | 4.17 | Â |
lungs metastases, failure after both ECF and Paclitaxel+DDP | Change regimen and continue chemotherapy | Â | Â | Â | Â | Â | Â | 0.351 |
Change regimen and continue chemotherapy | Â | 86 | 85.15 | 122 | 75.78 | 60 | 62.50 | Â |
Best supportive care | Â | 13 | 12.87 | 35 | 21.74 | 31 | 32.29 | Â |
Other | Â | 2 | 1.98 | 4 | 2.48 | 5 | 5.21 | Â |
lungs metastases, failure after both ECF and Paclitaxel+DDP, PS 3 | Best supportive care | Â | Â | Â | Â | Â | Â | 0.222 |
Change regimen and continue chemotherapy | Â | 18 | 17.82 | 15 | 9.32 | 9 | 9.38 | Â |
Best supportive care | Â | 79 | 78.22 | 136 | 84.47 | 81 | 84.38 | Â |
Other | Â | 4 | 3.96 | 10 | 6.21 | 6 | 6.25 | Â |